Novel agent for treatment of Parkinson's disease in clinical development
"Lu AA47070 is a very promising compound with a unique profile and has the potential to make a significant difference to for instance patients suffering from Parkinson's disease," says Peter Høngaard Andersen, Head of Research at Lundbeck. He continues: "Lu AA47070 is discovered at Lundbeck and is our first compound within the neurology area from our internal research.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.